Perioperative Statins to Prevent AFib After Lung Surgery

NCT07727681 | Recruiting Phase 4 DMC

• 2 other identifiers: K112132026-PUMCH-A-090
• Study Type: interventional
• Target: 540
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this clinical trial is to learn whether short-term treatment with atorvastatin can prevent new abnormal rapid heart rhythms after lung surgery in adults aged 60 years or older who are scheduled to have a lung segment or lung lobe removed. The study will also evaluate the safety of short-term atorvastatin treatment around the time of surgery. The main questions this study aims to answer are:

• Does perioperative atorvastatin lower the number of participants who develop atrial fibrillation or a related rapid rhythm from the upper chambers of the heart during the first 72 hours after surgery?
• What medical problems or changes in liver, kidney, or muscle-related laboratory tests occur during treatment? Participants will be assigned by chance to receive either short-term atorvastatin treatment or a matching placebo-based comparison treatment. A placebo is a look-alike tablet that does not contain atorvastatin. Participants who were already taking a statin (moderate-intensity) before the study will receive a standardized background statin regimen so that their usual treatment is not stopped unnecessarily. Neither the participants nor most members of the research team will know which treatment has been assigned. Study treatment will usually begin 2 to 7 days before surgery and continue until 72 hours after surgery. After surgery, participants will wear a portable heart monitor continuously for 72 hours to identify abnormal heart rhythms. Researchers will also collect routine clinical information, blood test results, and safety information during the hospital stay and will follow participants for 30 days after surgery.

Conditions

Postoperative Atrial Fibrillation; Lung Surgery

Outcome Measures

Primary Outcomes (1)

• Number of Participants With New-Onset Postoperative Atrial or Supraventricular Tachyarrhythmia (Postoperative Atrial Fibrillation, POAF)

  The number of participants with at least one new electrocardiographically documented episode of atrial fibrillation, atrial flutter, atrial tachycardia, or other supraventricular tachycardia lasting at least 30 seconds. Events will be detected primarily by continuous single-lead Holter monitoring for 72 hours after surgery. Bedside electrocardiographic monitoring and 12-lead electrocardiograms will be used as additional supporting evidence. Each participant will be counted once, regardless of the number of qualifying episodes.

  From the end of surgery through 72 hours after surgery

Study Arms (2)

Perioperative Atorvastatin 40 mg

EXPERIMENTAL

Participants will receive atorvastatin 40 mg orally once daily, administered as two 20-mg tablets. Treatment will usually begin 2 to 7 days before surgery and continue until 72 hours after surgery.

Drug: Atorvastatin

Placebo-Based Comparator

PLACEBO COMPARATOR

Statin-naive participants/Participants receiving long-term low-intensity statin therapy will receive two matching placebo tablets orally once daily. Participants receiving long-term moderate-intensity statin therapy before enrollment will receive atorvastatin 20 mg plus one matching placebo tablet once daily. Treatment will usually begin 2 to 7 days before surgery and continue until 72 hours after surgery.

Drug: Atorvastatin; Drug: Matching Placebo

Interventions

Atorvastatin DRUG

Atorvastatin will be administered orally once daily using 20-mg tablets. Participants assigned to the experimental arm will receive atorvastatin 40 mg daily as two 20-mg tablets. Participants who were receiving long-term moderate-intensity statin therapy before enrollment and are assigned to the comparator arm will receive atorvastatin 20 mg daily together with one matching placebo tablet. Treatment will usually begin 2 to 7 days before surgery and continue until 72 hours after surgery.

Perioperative Atorvastatin 40 mg; Placebo-Based Comparator

Matching Placebo DRUG

The matching placebo will be manufactured to resemble the atorvastatin 20-mg tablet in appearance and packaging. Statin-naive participants/Participants receiving long-term low-intensity statin therapy assigned to the comparator arm will receive two matching placebo tablets orally once daily. Participants receiving long-term moderate-intensity statin therapy before enrollment and assigned to the comparator arm will receive one matching placebo tablet together with atorvastatin 20 mg once daily. Treatment will usually begin 2 to 7 days before surgery and continue until 72 hours after surgery.

Placebo-Based Comparator

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 60 years or older.
• Scheduled to undergo isolated anatomical lung resection, including pulmonary segmentectomy or lobectomy.
• Sinus rhythm documented by a preoperative electrocardiogram.
• Not receiving antiarrhythmic medication, with the exception of beta-blockers.
• Willing and able to provide written informed consent.

You may not qualify if:

• Untreated hyperthyroidism or hypothyroidism.
• History of obstructive hepatobiliary disease, active liver disease, or other serious liver disease.
• Preoperative serum creatinine greater than 150 μmol/L.
• Known allergy to atorvastatin or another statin, or a history of a serious statin-related adverse reaction, including statin-associated myopathy.
• Personal or family history of an inherited muscle disorder.
• Continuous use within 1 month before randomization of fibrates, niacin, or medications that strongly inhibit cytochrome P450 or P-glycoprotein, including cyclosporine, oral azole antifungal agents, certain interacting antibiotics, protease inhibitors, nefazodone, or amiodarone.
• Consumption of 1 liter or more of grapefruit juice per day within 1 month before randomization.
• Current treatment with a high-intensity statin regimen, including atorvastatin 40 mg/day or higher or rosuvastatin 20 mg/day or higher.
• Any other condition that, in the investigator's judgment, would make participation unsafe or interfere with the conduct or evaluation of the study.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (2)

Peking Union Medical College Hospital

Beijing, China

NOT YET RECRUITING

Peking Union Medical College Hospital

Beijing, China

RECRUITING

MeSH Terms

Interventions

Atorvastatin

Intervention Hierarchy (Ancestors)

Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heptanoic Acids; Fatty Acids; Lipids

Central Study Contacts

Tao Lu, MD,PhD

CONTACT

01069152630; lutaowhiz@sina.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 22, 2026
• First Posted: July 27, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): January 2, 2028
• Last Updated: July 28, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)